MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Johnson and Johnson

Cerrado

SectorSalud

155.4 1.44

Resumen

Variación precio

24h

Actual

Mínimo

153.18

Máximo

155.77

Métricas clave

By Trading Economics

Ingresos

3.4B

Ventas

20M

23B

P/B

Media del Sector

28.643

63.778

BPA

2.04

Rentabilidad por dividendo

2.99

Margen de beneficio

15.235

Empleados

138,100

EBITDA

652M

5.9B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+9.9% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.99%

2.39%

Próximas Ganancias

15 abr 2025

Próxima Fecha de Ex Dividendo

19 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

32B

400B

Apertura anterior

153.96

Cierre anterior

155.4

Noticias sobre sentimiento de mercado

By Acuity

62%

38%

339 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Johnson and Johnson Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

10 mar 2025, 15:16 UTC

Principales Movimientos del Mercado

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10 mar 2025, 13:59 UTC

Principales Movimientos del Mercado

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

2 abr 2025, 12:49 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Expects 2026 Earnings Dilution to Be Reduced to About 21c/Shr

2 abr 2025, 12:49 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Expects Deal to Dilute Adj EPS by About 25c in 2025 >JNJ

2 abr 2025, 12:48 UTC

Adquisiciones, fusiones, absorciones

J&J: Deal Expected to Accelerate 2025 Sales Growth by About 0.8% With About $700M in Incremental Sales >JNJ

2 abr 2025, 12:45 UTC

Adquisiciones, fusiones, absorciones

J&J: Addition of CAPLYTA Strengthens Lineup of Therapies With $5 Billion+ Potential in Peak Yr Sales >JNJ

2 abr 2025, 12:44 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: sNDA Submitted to FDA for CAPLYTA as Adjunctive Treatment for Major Depressive Disorder >JNJ

2 abr 2025, 12:44 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Closes Landmark Intra-Cellular Therapies Acquisition to Solidify Neuroscience Leadership

1 abr 2025, 20:07 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1 abr 2025, 16:09 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, Johnson & Johnson, Southwest, Delta, MicroStrategy, PVH, Newsmax, and More -- Barrons.com

1 abr 2025, 13:51 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, Johnson & Johnson, PVH, Southwest, Newsmax, and More -- Barrons.com

1 abr 2025, 12:15 UTC

Principales Noticias

Johnson & Johnson Stock Falls After Latest Talc Resolution Rejected -- Barrons.com

1 abr 2025, 11:37 UTC

Charlas de Mercado

Johnson & Johnson To Reverse $7 Billion of Talc Reserve -- Market Talk

1 abr 2025, 10:36 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, XPeng, PVH, Progress Software, J&J, Newsmax, Southwest, and More -- Barrons.com

1 abr 2025, 01:04 UTC

Principales Noticias

Johnson & Johnson's Third Bankruptcy Case for Talc Lawsuits Thrown Out -- WSJ

21 mar 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

21 mar 2025, 13:35 UTC

Ganancias
Acciones populares

Stocks to Watch Friday: J&J, Nike, FedEx, Micron -- WSJ

14 mar 2025, 09:30 UTC

Principales Noticias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

7 mar 2025, 01:00 UTC

Principales Noticias

Finance Executives Seek Stability Amid Erratic Tariff Shifts -- WSJ

18 feb 2025, 22:22 UTC

Principales Noticias

Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan -- Update

14 feb 2025, 13:00 UTC

Principales Noticias

J&J's High Hopes for Heart-Rhythm Device Grounded by Safety Concerns -- WSJ

24 ene 2025, 07:00 UTC

Principales Noticias

Disasters Spawn New Businesses. The California Wildfires Will Do the Same. -- Barrons.com

22 ene 2025, 21:39 UTC

Ganancias

These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 ene 2025, 19:41 UTC

Ganancias

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 ene 2025, 17:38 UTC

Charlas de Mercado
Ganancias

J&J's Forex Headwind in Outlook Surprised Investors -- Market Talk

22 ene 2025, 16:48 UTC

Ganancias

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 ene 2025, 14:51 UTC

Ganancias

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Ford, and More -- Barrons.com

22 ene 2025, 14:09 UTC

Principales Noticias
Ganancias

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 ene 2025, 13:04 UTC

Ganancias

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Travelers, and More -- Barrons.com

22 ene 2025, 12:47 UTC

Ganancias

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Agilysys, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Johnson and Johnson Esperado

Precio Objetivo

By TipRanks

9.9% repunte

Estimación a 12 meses

Media 168.42 USD  9.9%

Máximo 185 USD

Mínimo 152 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Johnson and Johnson Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

14 ratings

6

Comprar

8

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 164.25Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

339 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.